Asthma Trial, Recruiting NCT07489911 Sponsor: Chiesi Slovenija, d.o.o. Condition: Asthma
Back to Asthma

Asthma Trial, Recruiting

NCT07489911
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been formally diagnosed with asthma by a doctor (following established international guidelines) and have been receiving treatment for asthma for at least 3 years before joining the study
  • Adults aged 18 or older who are receiving outpatient care (not currently admitted to hospital)
  • People whose asthma is not well controlled despite already using a combination of inhaled medicines (a long-acting beta-agonist plus high-dose inhaled corticosteroids, with or without an additional inhaled medicine called a LAMA), taken for at least 3 months
  • People whose asthma meets the medical criteria for a specific inhaler medicine (Trimbow 172/5/9 μg), which includes: having had at least one asthma flare-up requiring steroid tablets or injections in the past 12 months; having asthma that is uncontrolled or only partially controlled based on a standard symptom score; and having a breathing test result below 80% of the expected level
  • People who have recently been switched to the study inhaler (Trimbow 172/5/9 μg) no more than one week before joining, or who are switched on the day of joining
  • People who have given written agreement to take part in the study

Who may not be able to join:

  • People who have taken part in another clinical trial within the past 30 days
  • People who were admitted to hospital because of an asthma flare-up within the 4 weeks before enrolling
  • People who have another lung or breathing condition (other than asthma or COPD) that could affect how well the study treatment works, or who have another significant health situation that could make it difficult to use the treatment consistently
  • People who regularly use high-dose steroid tablets or steroid injections on an ongoing basis (above specified daily dose thresholds)
  • People who rely on continuous oxygen therapy
  • People who have had any cancer in the last 5 years
  • People who have active tuberculosis or a history of tuberculosis
  • People who are currently using, or have used in the past 12 months, biologic medicines for asthma treatment
  • People who meet any of the additional exclusion conditions listed in the official prescribing information for the Trimbow 172/5/9 μg inhaler (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +38640292828

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Chiesi Slovenija, d.o.o.
Registry
ClinicalTrials.gov
Start date
4 November 2024
Est. completion
1 July 2026

Where this trial is recruiting

🇸🇮 Slovenia

Primary endpoints

Asthma Control Test; Asthma Control Test 2

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov